Financings In Brief: Trimeris

Trimeris: Completes $10.1 mil. offering of preferred series B stock consisting of new funding and the conversion of existing bridge-financing operations, the Research Triangle Park, N.C.-based antiviral drug development company announces. Participants in the offering include Domain Partners II, Biotechnology Investments Limited, Sentron Medical, Dominion Ventures, and Domain Partners III. The funding will help the company begin clinical trials of T-20, a selective inhibitor of HIV-1. Trimeris says "a patent will be granted" for T-20 and that clinical trials will begin in early 1996...